Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for two medicines.
- Glecaprevir/pibrentasvir (Maviret®) coated granules are recommended as an option to treat children aged 3 years to under 12 years with long-lasting (chronic) hepatitis C. This is an infectious disease that affects the liver, caused by the hepatitis C virus.
- Ustekinumab (Stelara®) solution for injection is recommended as an option for the treatment of severe plaque psoriasis in children from the age of 6 to 11 years, in line with NICE guidance for adults and adolescents. Plaque psoriasis is a skin condition that causes inflammation affecting the skin and nails.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.